CBLL

CeriBell Inc

Add to Watchlist

Advanced Chart

16.360

+0.170(+1.050%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

16.675

Open

16.240

VWAP

16.36

Vol

272.02K

Mkt Cap

586.81M

Low

15.645

Amount

4.45M

EV/EBITDA(TTM)

Total Shares

35.82M

405.18M

EV/OCF(TTM)

P/S(TTM)

8.53

Ceribell, Inc. is a commercial-stage medical technology company. It is focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Point-of-Care EEG enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. Its Clarity AI algorithm interprets EEG in real-time, provides bedside alerts and continuous monitoring for status epilepticus. The Ceribell EEG Portal makes it easy to remotely review EEG in real-time with pre-annotated EEG insights.

5 Analyst Rating

103.24% Upside

Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 33.25 USD with a low forecast of 32.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

103.24% Upside

Current: 16.360

Low

32.00

Averages

33.25

High

36.00

103.24% Upside

Current: 16.360

Low

32.00

Averages

33.25

High

36.00

Ladenburg Thalmann

Jeff Cohen

Strong Buy

Initiates

$32

2025-04-04

Reason

Ladenburg Thalmann

Jeff Cohen

Price Target

$32

2025-04-04

Initiates

Strong Buy

Reason

Ladenburg initiated coverage of Ceribell with a Buy rating and $32 price target. The company has a first-mover advantage in scaling rapid electroencephalography technology for acute neurological care, the analyst tells investors in a research note.

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$33

2025-02-26

Reason

Canaccord Genuity

William Plovanic

Price Target

$33

2025-02-26

Maintains

Strong Buy

Reason

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$31 → $33

2024-12-09

Reason

Canaccord Genuity

William Plovanic

Price Target

$31 → $33

2024-12-09

Maintains

Strong Buy

Reason

Canaccord raised the firm's price target on Ceribell to $33 from $31 and keeps a Buy rating on the shares. Canaccord said they are bullish on the Med-Tech sector heading into 2025 as they expect investor interest to increase given smid-cap valuations continue to remain depressed while M&A has picked up and the IPO market seems to have opened. They highlight how AI is changing the space and are seeing continued interest in value-based care in the US, and believe that med-tech is well positioned to help drive the trend for improving patient outcomes while also reducing overall costs.

TD Cowen

Joshua Jennings

Strong Buy

Maintains

$31 → $36

2024-12-09

Reason

TD Cowen

Joshua Jennings

Price Target

$31 → $36

2024-12-09

Maintains

Strong Buy

Reason

TD Cowen analyst Joshua Jennings raised the firm's price target on Ceribell to $36 from $31 and keeps a Buy rating on the shares. The firm said its target increase reflects a slightly higher EV/sales multiple of 10.5 applied to their unchanged 2026 estimate and an updated share count.

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$30 → $31

2024-11-13

Reason

Canaccord Genuity

William Plovanic

Price Target

$30 → $31

2024-11-13

Maintains

Strong Buy

Reason

Canaccord raised the firm's price target on Ceribell to $31 from $30 and keeps a Buy rating on the shares. The firm said its first conference call as a public company was fairly straightforward, with the only new incremental news since our initiation was the company's recent authority to operate from the US Department of Veterans Affairs, which unlocks the VA and being able to connect to their networks for Ceribell.

TD Cowen

Joshua Jennings

Strong Buy

Initiates

$31

2024-11-05

Reason

TD Cowen

Joshua Jennings

Price Target

$31

2024-11-05

Initiates

Strong Buy

Reason

TD Cowen initiated coverage of Ceribell with a Buy rating and $31 price target. The company's technology tackles the limitations of conventional EEG in the acute care setting, the analyst tells investors in a research note. The firm says this offers workflow benefits to physicians and staff and economic benefits to hospitals.

See All Ratings

Valuation Metrics

The current forward P/E ratio for CeriBell Inc (CBLL.O) is -9.52, compared to its 5-year average forward P/E of -14.90. For a more detailed relative valuation and DCF analysis to assess CeriBell Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-14.90

Current PE

-9.52

Overvalued PE

-8.27

Undervalued PE

-21.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-17.87

Current EV/EBITDA

-6.46

Overvalued EV/EBITDA

-8.58

Undervalued EV/EBITDA

-27.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

9.59

Current PS

6.56

Overvalued PS

13.35

Undervalued PS

5.83

Financials

Annual

Quarterly

FY2024Q4

YoY :

+41.15%

18.53M

Total Revenue

FY2024Q4

YoY :

+53.75%

-12.88M

Operating Profit

FY2024Q4

-12.58M

Net Income after Tax

FY2024Q4

YoY :

+45.83%

-0.35

EPS - Diluted

FY2024Q4

-10.47M

Free Cash Flow

FY2024Q4

YoY :

+3.48%

87.61

Gross Profit Margin - %

FY2024Q4

YoY :

-18.11%

-55.99

FCF Margin - %

FY2024Q4

YoY :

+7.70%

-67.85

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

376.9K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

10.5M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

6.1M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

376.9K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

10.5M

USD

Months

0-12

0.0

USD

Months

CBLL News & Events

Events Timeline

2025-04-15 (ET)

2025-04-15

08:17:58

Ceribell announces FDA grants clearance for next-gen Ceribell Clarity algorithm

2025-04-11 (ET)

2025-04-11

13:40:00

Ceribell jumps after saying no impact from incremental tariffs until Q4

2025-02-25 (ET)

2025-02-25

16:23:41

Ceribell sees FY25 revenue $81M-$85M, consensus $81.32M

News

9.0

04-15Newsfilter

FDA Clears Ceribell's Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older

9.5

04-11Benzinga

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday

4.0

04-04Benzinga

This Lattice Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday